ClinicalTrials.gg
CompletedNCT00408187ESSENCEUpdated Jul 30, 2009

Randomized, Placebo and Ciclosporin Controlled Study of ISA247 in Plaque Psoriasis Patients

A Phase 3 interventional study of voclosporin and Ciclosporin in Psoriasis, sponsored by Aurinia Pharmaceuticals Inc.. Completed at 49 sites in 3 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2009-07-30.

Sponsored by Aurinia Pharmaceuticals Inc. · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
642
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 299 studies in Psoriasis with a site in Germany — 13 open to participants now, 30 under way, 15 of them phase 3. Psoriasis · Germany.

Enrollment
56th of 260
642 · median 196
Started
2006
with 7 others
Phase 3
121 of 299
5 open now
Registered
22nd of 299
by date

Among the 299 studies in Psoriasis with a site in Germany, this one is the 56th largest by enrollment of the 260 interventional ones that give a count, is one of 8 that started in 2006, is one of 121 in phase 3, and was the 22nd registered.

Psoriasis

2,030 studies on the registry are indexed under Psoriasis; 276 are open to participants now.

Browse Psoriasis studies →

Open to participants now

13 of the 299 studies in Psoriasis with a site in Germany are open now. Recruiting first, the newest first:

8 more — sign in →

All 13 open studies →

A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →

Who these studies take

Of the 173 Psoriasis studies recruiting now, 91 (53%) set no upper age limit and 66 (38%) stop at 75 or younger; 25 take children under 18; 40 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 299 studies in Psoriasis with a site in Germany, or all of them as a file.
02

Study summary

The purpose of this study is to determine the safety and efficacy of voclosporin in patients with plaque psoriasis.

Read the detailed description

Psoriasis is a chronic skin condition that can have a significant impact on a patient's physical and mental well being. The most common form of psoriasis is plaque psoriasis. Targeted treatments in psoriasis have been reported recently, yet ciclosporin, a calcineurin inhibitor (CNi) remains one of the treatments which has the greatest efficacy. Voclosporin represents the possibility of a calcineurin inhibitor which is not only as efficacious as ciclosporin A, but also has an improved toxicity profile.

03

Conditions studied

  • Psoriasis

Keywords

  • Randomized Controlled Trials
  • Immunosuppression
  • Adult
  • Chronic Disease
  • Dermatologic Agents
  • Female
  • Humans
  • Male
  • Middle Aged
  • Severity of Illness Index
  • Treatment Outcome
  • Quality of Life
  • Double-Blind Method
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Aged greater than or equal to 18 years of age inclusive at time of screening.
  • Diagnosed with plaque psoriasis greater than or equal to 6 months prior to screening.
  • Diagnosis of stable, plaque psoriasis; i.e. psoriasis must not be spontaneously improving or worsening in the 4 weeks prior to the screening visit.
  • Psoriasis failing at least one systemic treatment regimen or where other systemic therapies are or where tolerability is an issue.
  • Plaque psoriasis involving greater than or equal to 10% of the body surface area and a SPGA score greater than or equal to 3 at screening and prior to randomization at the day 0 visit.
  • Not pregnant or nursing.
  • Sexually active women of or less than 1 year and sexually active men who are not surgically sterile must use a reliable form of during study treatment and for at least 3 months after the last dose of study drug. Surgically sterile females are not considered to be of childbearing potential. Reliable forms of birth control include oral or depot contraceptives, and double-barrier methods.
  • Written prior to washout and screening procedures.
  • Able to keep study appointments and cooperate with all study requirements, in the opinion of the Investigator.

Exclusion criteria

Exclusion Criteria:

  • Has generalized erythrodermic, guttate, or pustular psoriasis.
  • Have other dermatoses that would interfere with the evaluation of psoriasis, at the discretion of the Investigator.
  • A current or history of malignancy within 5 years or a history of lymphoma at any time. Subjects can be enrolled with a history of squamous or basal cell carcinoma that has been surgically excised or removed with curettage and electrodesiccation.
  • Has a current, uncontrolled bacterial, viral, or fungal infection that requires intravenous antibiotics or antifungals or has had such infections within 60 days prior to screening.
  • A known history of tuberculosis.
  • Serologic evidence or known latent , or virus.
  • Uncontrolled hypertension of systolic blood pressure greater than or equal to 160 mmHg or diastolic blood pressure greater than or equal to 90 mmHg.
  • GFR \< 60 mL/min.
  • Variation between the screening and Visit 1 SCr greater than or equal to 30%.
  • , AST, GGT greater than or equal to 2x (ULN).
  • White blood cell count less than or equal to 2.8 x 10 to the ninth power/L.
  • Requires the following prohibited medications or treatments during the or treatment period: drugs potentiating the nephrotoxicity of voclosporin, drugs interfering with its pharmacokinetics, drugs considered to contribute to psoriasis flare; or, systemic and topical psoriasis medication that may interfere with assessment of study drug efficacy.
  • Has used any drug or device within 30 days or 10 half lives (whichever is longer) prior to the screening visit.
  • Current participation in another clinical trial of any drug or biological agent.
  • Has taken biological agent(s), except flu shots, tetanus shots, or boosters, within 3 months of randomization. Biological agents include any virus, , therapeutic serum, toxin, antitoxin, monoclonal antibodies or analogous product applicable to the prevention, treatment, or cure of diseases or injuries of man.
  • Previous exposure to voclosporin.
  • A history of clinically defined allergy to ciclosporin, constituents of Neoral or any of the constituents of the ISA247 formulation.
  • A history of alcoholism or drug addiction.
  • Weighs \< 45kg (99 lbs).
  • A history of disease, including mental/emotional disorder that would interfere with the subject's participation in the study, in the evaluation of his/her response or that might cause the administration of voclosporin to pose a significant risk to the subject, in the opinion of the Investigator.
Terms in these criteria, in plain language(15)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
642 participants (actual)

Study arms

  • Active comparator
    1.

    Drug: voclosporin

  • Placebo comparator
    3.

    Drug: Placebo

  • Active comparator
    2.

    Drug: Ciclosporin

Interventions

06

What researchers measure

Primary outcomes

  1. Superiority in the proportion of subjects achieving a score of "clear" or "almost clear" in the Static Physician's Global Assessment (SPGA) score

    Time frame: Twelve weeks of treatment

Secondary outcomes

  1. To show non-inferiority of voclosporin compared to ciclosporin in the proportion of subjects achieving a score of "clear" or "almost clear" in the Static Physician's Global Assessment (SPGA) score at

    Time frame: Twelve weeks of treatment

  2. Superiority in de novo hypertriglyceridemia, defined as proportion of patients developing fasting triglycerides greater than or equal to 1.7 mmol/L

    Time frame: Twenty four weeks of treatment

  3. Superiority in de novo hypertension, defined as proportion of patients developing blood pressure greater than or equal to 140 mmHg (systolic) or greater than or equal to 90 mmHg (diastolic)

    Time frame: Twenty four weeks of treatment

  4. Superiority of renal function, defined as the proportion of patients experiencing a confirmed greater than or equal to 30% rise in serum creatinine

    Time frame: Twenty four weeks of treatment

  5. Superiority in proportion of patients achieving a 75% reduction in the Psoriasis Area and Severity Index (PASI) score (PASI-75)

    Time frame: Twelve weeks of treatment

07

Study locations

49 sites
  • Isotechnika Investigational Site
    Edmonton, Alberta T5X 1X3, Canada
  • Isotechnika Investigational Site
    Surrey, British Columbia V3R 6A7, Canada
  • Isotechnika Investigational Site
    Vancouver, British Columbia V5Z 4E8, Canada
  • Isotechnika Investigational Site
    St. John's, Newfoundland and Labrador A1B 3E1, Canada
  • Isotechnika Investigational Site
    St. John's, Newfoundland and Labrador A1B 4F8, Canada
  • Isotechnika Investigational Site
    Halifax, Nova Scotia B3H 1Z4, Canada
  • Isotechnika Investigational Site
    Barrie, Ontario L4M 6L2, Canada
  • Isotechnika Investigational Site
    London, Ontario N5X 2P1, Canada
  • Isotechnika Investigational Site
    Markham, Ontario L3P 1A8, Canada
  • Isotechnika Investigational Site
    North Bay, Ontario P1B 3Z7, Canada
  • Isotechnika Investigational Site
    Ottawa, Ontario K2G 6E2, Canada
  • Isotechnika Investigational Site
    Waterloo, Ontario N2J 1C4, Canada
  • Isotechnika Investigational Site
    Montreal, Quebec H2K 4L5, Canada
  • Isotechnika Investigational Site
    Montreal, Quebec H3H 1V4, Canada
  • Isotechnika Investigational Site
    Québec, Quebec G1V 4X7, Canada
  • Isotechnika Investigational Site
    Ausburg, 86179, Germany
  • Isotechnika Investigational Site
    Berlin, 10117, Germany
  • Isotechnika Investigational Site
    Berlin, 10435, Germany
  • Isotechnika Investigational Site
    Berlin, 10437, Germany
  • Isotechnika Investigational Site
    Berlin, 10827, Germany
  • Isotechnika Investigational Site
    Bochum, 44787, Germany
  • Isotechnika Investigational Site
    Bochum, 44791, Germany
  • Isotechnika Investigational Site
    Dresden, 01097, Germany
  • Isotechnika Investigational Site
    Dresden, 01307, Germany
  • Isotechnika Investigational Site
    Frankfurt, 60590, Germany
  • Isotechnika Investigational Site
    Geiβen, 35390, Germany
  • Isotechnika Investigational Site
    Hamburg, 20246, Germany
  • Isotechnika Investigational Site
    Hamburg, 20354, Germany
  • Isotechnika Investigational Site
    Hansestadt Salzwedel, 29410, Germany
  • Isotechnika Investigational Site
    Kiel, 24105, Germany
  • Isotechnika Investigational Site
    Leipzig, 04103, Germany
  • Isotechnika Investigational Site
    Lübeck, 23538, Germany
  • Isotechnika Investigational Site
    Mahlow, 15831, Germany
  • Isotechnika Investigational Site
    Mainz, 55131, Germany
  • Isotechnika Investigational Site
    Münster, 48149, Germany
  • Isotechnika Investigational Site
    Potsdam, 14480, Germany
  • Isotechnika Investigational Site
    Wuppertal, 42275, Germany
  • Isotechnika Investigational Site
    Bialystock, 15-540, Poland
  • Isotechnika Investigational Site
    Bydgoszcz, 85-096, Poland
  • Isotechnika Investigational Site
    Gliwice, 44-100, Poland
  • Isotechnika Investigational Site
    Iwonicz-Zdrój, 38-440, Poland
  • Isotechnika Investigational Site
    Krakow, 31-501, Poland
  • Isotechnika Investigational Site
    Lodz, 91-347, Poland
  • Isotechnika Investigational Site
    Lublin, 02-080, Poland
  • Isotechnika Investigational Site
    Poznan, 60-355, Poland
  • Isotechnika Investigational Site
    Szczcin, 70-111, Poland
  • Isotechnika Investigational Site
    Warsaw, 02-008, Poland
  • Isotechnika Investigational Site
    Warzszawa, 02-008, Poland
  • Isotechnika Investigational Site
    Zabrze, 41-800, Poland
08

References and documents

Publications

  • Gregory CR, Kyles AE, Bernsteen L, Wagner GS, Tarantal AF, Christe KL, Brignolo L, Spinner A, Griffey SM, Paniagua RT, Hubble RW, Borie DC, Morris RE. Compared with cyclosporine, ISATX247 significantly prolongs renal-allograft survival in a nonhuman primate model. Transplantation. 2004 Sep 15;78(5):681-5. doi: 10.1097/01.tp.0000131950.75697.71. PubMed 15371668 ↗
  • Stalder M, Birsan T, Hubble RW, Paniagua RT, Morris RE. In vivo evaluation of the novel calcineurin inhibitor ISATX247 in non-human primates. J Heart Lung Transplant. 2003 Dec;22(12):1343-52. doi: 10.1016/s1053-2498(03)00033-0. PubMed 14672749 ↗
  • Abel MD, Aspeslet LJ, Freitag DG, Naicker S, Trepanier DJ, Kneteman NM, Foster RT, Yatscoff RW. ISATX247: a novel calcineurin inhibitor. J Heart Lung Transplant. 2001 Feb;20(2):161. doi: 10.1016/s1053-2498(00)00290-4. No abstract available. PubMed 11250240 ↗
  • Bissonnette R, Papp K, Poulin Y, Lauzon G, Aspeslet L, Huizinga R, Mayo P, Foster RT, Yatscoff RW, Maksymowych WP; ISA247 Psoriasis Study Group. A randomized, multicenter, double-blind, placebo-controlled phase 2 trial of ISA247 in patients with chronic plaque psoriasis. J Am Acad Dermatol. 2006 Mar;54(3):472-8. doi: 10.1016/j.jaad.2005.10.061. Epub 2006 Jan 23. PubMed 16488299 ↗
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Dec 2006, a primary completion of Dec 2008 and a completion of Dec 2008. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 4, 2006
First posted
Dec 6, 2006
Start
Dec 2006
Primary completionActual
Dec 2008
CompletionActual
Dec 2008
Last update
Jul 30, 2009
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 30, 2009, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00408187
Lead sponsor
Aurinia Pharmaceuticals Inc.
First posted
Dec 6, 2006
Start date
Dec 2006
Primary completion
Dec 2008
Completion
Dec 2008
Last update
Jul 30, 2009

Study contacts

Wayne Gulliver, M.D.
principal investigator · NewLab Clinical Research
Vincent Ho, M.D.
principal investigator · UBC
Andrzej Langner, Prof. Dr.
principal investigator · IWOLANG
Thomas A. Luger, Prof. Dr.
principal investigator · Universität Münster
Slawomir Majewski, Prof. Dr.
principal investigator · Akademia Medyczna
Wolfram Sterry, Prof. Dr.
principal investigator · Charite Universitatsmedizin Berlin

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2009. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Voclosporin · Cyclosporine

Start the discussion